# A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

> **NCT04108325** · PHASE1 · UNKNOWN · sponsor: **Shanghai YingLi Pharmaceutical Co. Ltd.** · enrollment: 58 (estimated)

## Conditions studied

- Relapsed or Refractory Peripheral T-Cell Lymphoma

## Interventions

- **DRUG:** YY-20394

## Key facts

- **NCT ID:** NCT04108325
- **Lead sponsor:** Shanghai YingLi Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03-30
- **Primary completion:** 2021-06
- **Final completion:** 2021-12
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2021-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04108325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04108325, "A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma". Retrieved via MORVS 2026-10-10 from https://api.morvs.ai/clinical/NCT04108325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*